Although direct targeting MYC for cancer therapy has been challenging [9, 26], the clinical data shown here would suggest that ATR-Chk1 pathway targeting could be an alternative anti-cancer approach in MYC-amplified breast cancers. The gene discussed is CHEK1; the disease is breast carcinoma.